<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen YL</submitter><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Wellcome Trust</funding><pagination>eadd9232</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615662</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(84)</volume><pubmed_abstract>Group A &lt;i>Streptococcus&lt;/i> (GAS) infection is associated with multiple clinical sequelae, including different subtypes of psoriasis. Such post-streptococcal disorders have been long known but are largely unexplained. CD1a is expressed at constitutively high levels by Langerhans cells and presents lipid antigens to T cells, but the potential relevance to GAS infection has not been studied. Here, we investigated whether GAS-responsive CD1a-restricted T cells contribute to the pathogenesis of psoriasis. Healthy individuals had high frequencies of circulating and cutaneous GAS-responsive CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells with rapid effector functions, including the production of interleukin-22 (IL-22). Human skin and blood single-cell CITE-seq analyses of IL-22-producing T cells showed a type 17 signature with proliferative potential, whereas IFN-γ-producing T cells displayed cytotoxic T lymphocyte characteristics. Furthermore, individuals with psoriasis had significantly higher frequencies of circulating GAS-reactive T cells, enriched for markers of activation, cytolytic potential, and tissue association. In addition to responding to GAS, subsets of expanded GAS-reactive T cell clones/lines were found to be autoreactive, which included the recognition of the self-lipid antigen lysophosphatidylcholine. CD8&lt;sup>+&lt;/sup> T cell clones/lines produced cytolytic mediators and lysed infected CD1a-expressing cells. Furthermore, we established cutaneous models of GAS infection in a humanized CD1a transgenic mouse model and identified enhanced and prolonged local and systemic inflammation, with resolution through a psoriasis-like phenotype. Together, these findings link GAS infection to the CD1a pathway and show that GAS infection promotes the proliferation and activation of CD1a-autoreactive T cells, with relevance to post-streptococcal disease, including the pathogenesis and treatment of psoriasis.</pubmed_abstract><journal>Science immunology</journal><pubmed_title>Group A &amp;lt;i&amp;gt;Streptococcus&amp;lt;/i&amp;gt; induces CD1a-autoreactive T cells and promotes psoriatic inflammation.</pubmed_title><pmcid>PMC7615662</pmcid><funding_grant_id>MC_UU_00036/2</funding_grant_id><funding_grant_id>100326/Z/12/Z</funding_grant_id><funding_grant_id>MC_UU_00036/5</funding_grant_id><funding_grant_id>MC_UU_00008</funding_grant_id><funding_grant_id>MC_UU_00008/6</funding_grant_id><funding_grant_id>MC_UU_00008/5</funding_grant_id><funding_grant_id>209222/Z/17/Z</funding_grant_id><funding_grant_id>NIHR203691</funding_grant_id><pubmed_authors>Dong T</pubmed_authors><pubmed_authors>Price DA</pubmed_authors><pubmed_authors>Nussbaum L</pubmed_authors><pubmed_authors>Gao F</pubmed_authors><pubmed_authors>Koohy H</pubmed_authors><pubmed_authors>Ng JSW</pubmed_authors><pubmed_authors>Ogg GS</pubmed_authors><pubmed_authors>Hardman CS</pubmed_authors><pubmed_authors>Kurupati P</pubmed_authors><pubmed_authors>Gileadi U</pubmed_authors><pubmed_authors>Duncan DA</pubmed_authors><pubmed_authors>Johnson D</pubmed_authors><pubmed_authors>Ottakandathil Babu R</pubmed_authors><pubmed_authors>Ladell K</pubmed_authors><pubmed_authors>Chen YL</pubmed_authors><pubmed_authors>Woo J</pubmed_authors><pubmed_authors>Nahler J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Group A &amp;lt;i&amp;gt;Streptococcus&amp;lt;/i&amp;gt; induces CD1a-autoreactive T cells and promotes psoriatic inflammation.</name><description>Group A &lt;i>Streptococcus&lt;/i> (GAS) infection is associated with multiple clinical sequelae, including different subtypes of psoriasis. Such post-streptococcal disorders have been long known but are largely unexplained. CD1a is expressed at constitutively high levels by Langerhans cells and presents lipid antigens to T cells, but the potential relevance to GAS infection has not been studied. Here, we investigated whether GAS-responsive CD1a-restricted T cells contribute to the pathogenesis of psoriasis. Healthy individuals had high frequencies of circulating and cutaneous GAS-responsive CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells with rapid effector functions, including the production of interleukin-22 (IL-22). Human skin and blood single-cell CITE-seq analyses of IL-22-producing T cells showed a type 17 signature with proliferative potential, whereas IFN-γ-producing T cells displayed cytotoxic T lymphocyte characteristics. Furthermore, individuals with psoriasis had significantly higher frequencies of circulating GAS-reactive T cells, enriched for markers of activation, cytolytic potential, and tissue association. In addition to responding to GAS, subsets of expanded GAS-reactive T cell clones/lines were found to be autoreactive, which included the recognition of the self-lipid antigen lysophosphatidylcholine. CD8&lt;sup>+&lt;/sup> T cell clones/lines produced cytolytic mediators and lysed infected CD1a-expressing cells. Furthermore, we established cutaneous models of GAS infection in a humanized CD1a transgenic mouse model and identified enhanced and prolonged local and systemic inflammation, with resolution through a psoriasis-like phenotype. Together, these findings link GAS infection to the CD1a pathway and show that GAS infection promotes the proliferation and activation of CD1a-autoreactive T cells, with relevance to post-streptococcal disease, including the pathogenesis and treatment of psoriasis.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2026-06-10T09:23:32.368Z</modification><creation>2025-04-04T07:49:00.988Z</creation></dates><accession>S-EPMC7615662</accession><cross_references><pubmed>37267382</pubmed><doi>10.1126/sciimmunol.add9232</doi></cross_references></HashMap>